AzTrials
AzTrials

Induction of Labor Affected Fetus / NewbornNCT03533699

A Comparison Between the Effect of Oxytocin Only and Oxytocin Plus Propranolol on Induction of Labor in Term Pregnancy

A study testing Propranolol in people with Induction of Labor Affected Fetus / Newborn, run by Ain Shams Maternity Hospital at 1 site in Egypt.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The present study is conducted to compare the effect of Oral Propranolol and Oxytocin, versus Oxytocin only on induction of labor in term pregnancy. Read more about this study

Who is it for?
Ages Up to 45 years, women onlyHealthy volunteers can take part
What is being tested?
Propranolol
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
202 participants
Where
1 siteEgypt
Study dates
1 Oct 2016to 1 Jan 2019
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Up to 45 years
  • Women only
  • Healthy volunteers accepted
  • Child, Adult

Who may be able to join

  • Gestational age of 38-41 weeks of pregnancy (according to a reliable last menstrual period (LMP) and sonography of first trimester)
  • Nulliparity,
  • Singleton pregnancy.
  • Cephalic presentation.
  • Intact membranes.
  • Bishop Score 5 or more.

Who cannot join

  • Pelvic contraction,
  • Previous surgical operation on the uterus,
  • Signs of fetal distress,
  • Placenta previa
  • Suspicious macrosomia,
  • Polyhydramnios,
  • Hydrocephalus of fetus
  • History of any known cardiac, pulmonary or metabolic disorder of mother, or maternal drug use.

Trial locations and contacts

1 site in 1 country.

Egypt1 site, 1 recruiting
  • Ain Shams university maternity hospital

    Cairo

    Recruiting

Other trials in Egypt

About this study

The present study is conducted to compare the effect of Oral Propranolol and Oxytocin, versus Oxytocin only on induction of labor in term pregnancy.

Read the detailed description

After receiving approval from the Hospital Ethics Committee, women with uncomplicated term pregnancy who will be admitted to the Ainshams maternity hospital will be recruited in this study.

Inclusion criteria:

  1. Gestational age of 38-41 weeks of pregnancy (according to a reliable last menstrual period (LMP) and sonography of first trimester)
  2. Nulliparity,
  3. Singleton pregnancy.
  4. Cephalic presentation.
  5. Intact membranes.
  6. Bishop Score 5 or more.

Exclusive criteria:

  1. Pelvic contraction,
  2. Previous surgical operation on the uterus,
  3. Signs of fetal distress,
  4. Placenta previa
  5. Suspicious macrosomia,
  6. Polyhydramnios,
  7. Hydrocephalus of fetus
  8. History of any known cardiac, pulmonary or metabolic disorder of mother, or maternal drug use.

Sample size calculation:

Assuming an effect size regarding interval until good contractions of 0.6(Ashraf DM et al., 2013), a sample size of 101 in each group would be enough to elucidate such effect if true, at 0.05 alpha error and 0.95 power of the test. Sample size could be inflated by 10% for dropouts so the total would be 112 in each group Sample size was calculated using sample size table calculation in designing clinical research appendix 6A (Hulley, S.B. et al., 2013)

Intervention to be done:

After taking informed consent, all pregnant ladies recruited in the study will undergo complete clinical examination and detailed medical history will be obtained along with necessary lab investigations and ultrasound findings. Each patient will have a case record form in which the following data will be recorded:

  • History: Personal (age, duration of marriage), present (any current medical or surgical diseases and any current medication), obstetric history (Gestational age, obstetric complications) and past history (cardiac, pulmonary or metabolic diseases).
  • Clinical examination:
  1. General examination: assessment of vital data, cardiac and chest auscultation to exclude contraindications for drug administration.
  2. Abdominal examination: assessment of fundal level and contractions.
  3. PV examination: assessment of Bishop score, membranes status and fetal presentation.
  • Investigations:
  1. Routine investigations will be done e.g., complete blood count and blood grouping.
  2. Pelvi-abdominal U/S (Confirm fetal life, placental location, fetus parameters, amniotic fluid index and expected fetal weight).
  • Confirmation of gestational age before 20 weeks' gestation (regular menstrual history with known last menstrual period and/or ultrasound confirmation of gestational age by means of crown rump length measurement in 1st trimester).
  • Assessment of uterine contractions and PV examination (cervical dilation and effacement, station of fetal head, fetal presentation, membranes status) are done and recorded and bishop score will be measured.
  • CTG will be done for all pregnant ladies included in the study.
  • Randomization:

Then Patients will be randomly assigned to two groups using sealed, sequentially distributed envelopes to which the letters A and B will be allocated. The letter A will be assigned to the propranolol group and the letters B to the oxytocin group. The envelopes, will be opened by the investigator, and according to the letters, the group of patients will be determined. The first vaginal examination will be performed by the investigator, and then the induction will be initiated by the same researcher. Continuation of induction and the control of patients will be monitored by a coworker who knew nothing about the method of initiation of induction, neither did the patients (double blind)

In the first group (Propranolol plus Oxytocin), a capsule consisting of 20 mg Propranolol will be administered and in the second group (Oxytocin plus placebo), a similar capsule as a placebo will be administrated orally by researcher before beginning of induction of labour.

Induction will be initiated at a dose of 2 mIu/min and it will be increased 2 mIu / minute every 15 minutes until good contractions are obtained (3 forceful contractions within 10 minutes) or to a maximum dose of 30 mIu/min; then, it will be continued at this rate for 8 hours. If patients enter the active phase of labour (cervical dilatation = 3-4 cm), induction will be continued until delivery. If no response to induction of labour, a caesarean section will be performed.

Blood pressures and heart rate of the parturients and fetal heart rates will be monitored every 15 minutes. The participants' characteristics, age, primary Bishop score, gestational age, the number of deliveries on the first day of induction and caesarean sections, timing of the beginning good contractions after induction, duration of latent phase (interval between the beginnings of good contractions until cervical dilatations of 3-4 cm will be obtained), type of delivery and Apgar scores of minutes 1 and 5, need of admissions to NICU and neonatal weights will be recorded and compared in the two groups. The participants will be followed up until delivery.

The partogram will be used to monitor the fetal heart rate, membranes status, cervical dilation and effacement, station of the fetus and uterine contractions (rate and strength).

After delivery mothers will be encouraged to establish skin to skin contact and breast feeding as soon as possible after birth. Babies will be encouraged to feed on demand but the interval between feeds will be no longer than 3 hours Samples for measuring blood glucose level for the newborn will be taken 1 hour after birth regardless of feeds, then before feeds 3-4 hourly in the first 24 hours. Measurements will be discontinued if there are 3 normal blood glucose concentration measurements and no clinical concerns about feeding.

Also fetal heart rate will be measured every 4 hours for 24 hours after delivery

Safety considerations:

If the parturient has hyperstimulation of contractions (in a situation with more than 5 contractions/10 mins, duration of contractions <90 secs, interval of contraction less than 2 min or fetal distress) the augmentation will be stopped and the parturient is kept in left lateral position and given oxygen, and intravenous dextrose.

Being tested
Propranolol, Placebo Oral Tablet

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PropranololDrug

    Also called beta blocker, indral

  • Placebo Oral TabletDrug

    oral tablets with no active drug

Study groups in NCT03533699
Study groupRoleWhat they receive
PropranololActive comparator101 women with uncomplicated term pregnancy who will be admitted to the Ain Shams University Maternity hospital and will receive syntocinon intravenous infusion for induction or augmentation of labour.
Receives: Drug: Propranolol
placeboPlacebo comparator101 women with uncomplicated term pregnancy who will be admitted to the Ain Shams University Maternity hospital and will receive syntocinon intravenous infusion for induction or augmentation of labour.
Receives: Drug: Placebo Oral Tablet

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Time from active phase to delivery in minutes

    Time from active phase to delivery in minutes

    Measured: 16 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 May 2018
  2. Study start1 Oct 2016
  3. Primary completion1 Jan 2019 (estimated)
  4. Study completion1 Jan 2019 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
In the first group (Propranolol plus Oxytocin), a capsule consisting of 20 mg Propranolol will be administered and in the second group (Oxytocin plus placebo), a similar capsule as a placebo will be administrated orally by researcher before beginning of induction of labour. Induction will be initiated at a dose of 2 mIu/min and it will be increased 2 mIu / minute every 15 minutes until good contractions are obtained (3 forceful contractions within 10 minutes) or to a maximum dose of 30 mIu/min; then, it will be continued at this rate for 8 hours. If patients enter the active phase of labour (cervical dilatation = 3-4 cm), induction will be continued until delivery. If no response to induction of labour, a caesarean section will be performed.
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
202 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03533699
Sponsor's protocol ID
propranolol, labor induction
Status last verified
Jan 2019
First submitted
23 Apr 2018
Last updated
14 Jan 2019
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Propranolol in people with Induction of Labor Affected Fetus / Newborn, run by Ain Shams Maternity Hospital at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 14 Jan 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Amr Riad, MD (01005347179 ext. +2, amr.riad@med.asu.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Time from active phase to delivery in minutes (time frame: 16 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jan 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in